Compounds of a new group of pentacyclic pyrroloquinones have been shown to have activity against several experimental tumour systems. The first product to be considered for clinical evaluation was GR30921X (NSC 382057) (Figure 1 ). The drug appeared to be inactive against L1210 and P388 leukaemias, but active in a range of solid tumours, including mouse sarcoma 180, rat hepatoma D23, human colon HT29 and human mammary MX-1 xenografts in athymic nude mice (Fenton et al., 1985) . Its mechanism of action, however, is undetermined. For clinical use the drug had to be formulated as a micro-crystalline suspension in low concentrations of polyethylene glycol 300 and propylene glycol (PEG/PG) to allow i.v. administration. In 1985 phase I trials started in a number of European cancer centers, but were discontinued with the introduction of the water soluble analogue, GR63178A. (Figure 1 ) has a similar preclinical efficacy profile to that of GR30921X including activity against mouse adenocarcinoma MAC 30/T, mouse colon 38 and the human lung xenograft LX-1 (Fenton et al., 1989) . Its toxicity profile in animals was shown to be relatively free of side effects and in particular, there was no evidence of bone-marrow suppression in animal models. Presently, the drug is in phase I trials in British and Dutch cancer centres (Cassidy et al., 1989; Eccles et al., 1989 , Verweij et al., 1989 .
GR63178A (NSC D611615)
Secondary screens with a disease-oriented approach have been developed which utilise a series of human tumour lines, derived from the same tumour type and grown in nude mice. These screens may add important information on the potential clinical activity and the differential capacity of promising anti-cancer compounds (Winograd et al., 1987; Boven et al., 1988) .
Concurrent with phase I clinical trials, we have investigated GR30921X and GR63178A for their efficacy in a panel of human ovarian cancer lines to analyse their potential activity in ovarian cancer in the clinical situation. Female NMRI/Cpb nude mice (Harlan Cpb, Zeist, Netherlands) maintained under sterile conditions were used (at the age of 8-10 weeks), 2-3 mm diameter tumour fragments being implanted in both flanks. The tumour lines studied originated from various ovarian cancer subtypes (Table I) , and had their own sensitivity patterns to conventional cytostatic drugs (Boven, 1988) . GR30921X (suspended in PEG/PG 1 mgml-') and GR63178A (dissolved in 5% dextrose 1-10mgml-') were kindly provided by Glaxo Group . For evaluation of treatment, relative tumour volumes were used, which were calculated with the formula VT! VO; where TT is the volume at any given day and Vo the volume at the start of treatment.
The ratio of the mean relative volume of treated tumours over that of control tumours multiplied by 100% (T/C%) indicated the drug activity. For each experiment the lowest value within 5 weeks after the last injection was considered E. BOVEN et al. the optimal ratio. Deaths within 2 weeks after the final injection were considered as toxic deaths, and these animals were excluded from the study. The drug activity was evaluated by Student's t test.
Initial experiments with GR30921X against tumour lines MRI-H-207, Ov.He and Ov.Me (Table II) , utilised either daily or weekly dose schedules at the MTD. With both schedules a remarkable growth inhibition of treated tumours could be obtained. After the withdrawal of GR30921X from clinical studies experiments were carried out with its successor, GR63178A, at doses and schedules similar to those of GR30921X. Slight activity was found against MRI-H-207, though this was less than that previously shown for GR30921X. In tumour lines Ov.He and Ov.Me efficacy was not observed. As GR63178A did not result in weight loss, doses were increased to the MTD using the same schedules i.e. 200 mg kg-' i.p. on days 0 and 7 or 75 mg kg-' i.p. daily on days 0-11. Ten different human ovarian cancer lines were studied either with both regimens or only the daily schedule (Table III) . In general, the daily schedule appeared to be more effective than the weekly administration (MRI-H-207, Ov.Gr, FMa and Ov.Pe). Tumour lines MRI-H-207, Ov.He, Ov.Me and Ov.Pe were the most sensitive to this agent; in MRI-H-207 and Ov.Pe T/C% was < 50%. Daily administration of GR63178A at a dose of 75 mg kg-' appeared to be more tolerable than a weekly dose of 200 mg kg-' (0/63 and 3/36 toxic deaths respectively).
From our results with GR30921X and GR63178A studied at MTD in a panel of human ovarian cancer lines we conclude that the efficacy of GR30921X is superior to that of the water soluble analogue. With GR63178A, presently in phase I clinical trials, we have shown that daily administration produces slightly better therapeutic effects than weekly injections. Moderate activity of this compound has been observed in 2/10 lines (T/C% >25% (50%) investigated. However, with reference to our previous results with conventional agents in nine of these lines its overall activity is less than cyclophosphamide (T/C% <25% in 2/9 lines) and cisplatin (T/C% <25% in 4/9 lines) (Table IV; Boven, 1988) . Whether the modest activity of GR63178A in our panel will reflect responses in ovarian cancer patients, should be awaited from future phase II clinical trials. (-) ; >25% 50% moderate activity (+); 25% high activity (++).
